Correlation between histopathological features and recurrence score according to menopausal status in HR+/HER2- breast cancer patients: a retrospective study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Histopathological features correlate differently with breast cancer recurrence scores based on menopausal status. Understanding these variations is key for refining risk stratification in early-stage hormone-receptor-positive, HER2-negative breast cancer patients.
Area Of Science
- Oncology
- Genomics
- Pathology
Background
- Traditionally, clinico-pathological features guide breast cancer (BC) prognosis and adjuvant therapy.
- Genomic tests like Oncotype DX refine risk stratification for hormone-receptor-positive (HR+)/human epidermal growth factor-receptor 2 negative (HER2-) BC patients.
- Menopausal status is a critical factor in BC, potentially influencing treatment response and prognosis.
Purpose Of The Study
- To investigate the correlation between histopathological parameters and the recurrence score (RS) in HR+/HER2- early BC patients.
- To analyze these correlations while accounting for menopausal status (pre- vs. post-menopausal).
- To identify specific clinico-pathological factors that predict RS in different menopausal groups.
Main Methods
- Retrospective analysis of 180 HR+/HER2- early BC patients who underwent Oncotype DX testing.
- Collected clinico-pathological data including tumor grade (G3), Ki67, estrogen receptor (ER%), and progesterone receptor (PgR%).
- Employed linear regression for continuous RS and logistic regression for dichotomized RS (thresholds 16 and 25) stratified by menopausal status.
Main Results
- Overall cohort showed significant RS correlations with G3, Ki67%, ER%, and PgR%.
- In pre-menopausal patients, Ki67%, ER%, and PgR% correlated significantly with RS; PgR% predicted RS > 16.
- In post-menopausal patients, G3, Ki67%, and PgR% correlated significantly; Ki67% and PgR% predicted RS > 25.
Conclusions
- Clinico-pathological features exhibit varying correlations with RS depending on menopausal status in HR+/HER2- early BC.
- These findings underscore the complexity of risk stratification and the need for personalized approaches.
- Further research is warranted to fully elucidate factors influencing RS and optimize its clinical utility across diverse patient populations.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...